MetaCap

Aura Biosciences (AURA) vs Bambusa Therapeutics (BBTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $715.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+11.89%BBTX+6.74%
+26%+11%-3%
Oct 30, 20261 yearNov 20, 2026
AURA+11.89%BBTX+6.74%
+17%+8%-1%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus BBTX key metrics
MetricAURABBTX
Share price$6.87$16.00
Market cap$714.99M$815.08M
1-day change-1.58%+2.89%
YTD return+26.06%—
1-year return+26.29%—
5-year return-69.63%—
EPS (TTM)$-1.59$-1.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-106.19M—
52-week high$9.54$17.65
52-week low$4.73$13.60
Distance from 52-week high-27.95%-9.35%
Analyst consensusstrong_buy—
Avg. price target upside+141.63%—
Average volume847.22K359.41K
Shares outstanding104.07M50.94M
Employees11326
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

AURA vs BBTX FAQ

Which is bigger, Aura Biosciences or Bambusa Therapeutics?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $714.99M for Aura Biosciences (AURA).

Are Aura Biosciences and Bambusa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons